Faster waning of the rubella-specific immune response in young pregnant women immunized with MMR at 15 months.
congenital rubella syndrome (CRS)
pregnant women
rubella
seropositivity rate
waning immunity
Journal
American journal of reproductive immunology (New York, N.Y. : 1989)
ISSN: 1600-0897
Titre abrégé: Am J Reprod Immunol
Pays: Denmark
ID NLM: 8912860
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
16
03
2020
revised:
10
06
2020
accepted:
16
06
2020
pubmed:
23
6
2020
medline:
28
8
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
Vaccination is the best protection against rubella and congenital rubella infection. Although a high rate of immunization coverage is achieved in Taiwan, it is unknown if the vaccine-induced immunity persists from the age of vaccination to childbearing age. A total of 5,988 prenatal rubella IgG test results of young pregnant women aged 19-23 years old from six hospitals during January 2001 to December 2008 and January 2013 to December 2017 were analyzed. We compared the rubella seropositivity rates and titers in these women who were vaccinated with MMR vaccine in four different vaccination age cohorts. The overall rubella seropositivity rate was 87.4% (95% CI: 86.6%-88.3%), and the mean rubella IgG level was 39 IU/mL among young pregnant women aged 19-23 years. Women in the elementary cohort had the highest rubella positivity of 90.8% (95% CI: 89.6%-91.9%), and levels gradually decrease to 84.6% (95% CI: 82.4%-86.7%) in 15-month plus cohort. The average rubella IgG was only 25 IU/mL for the 15-month plus cohort. Women in cohorts immunized at younger age exhibited significantly lower chances of being seropositive relative to women in older cohort after adjusting other factors (all P < .01). The rubella seropositivity rate and rubella IgG levels were low among young women aged 19-23 years, especially in cohorts immunized at younger age. As rubella immunity wanes over time, a third dose of MMR may be a protective strategy for women who conceive later in life.
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Measles-Mumps-Rubella Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13294Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet. 2015;385:2297-2307.
Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73:199-213.
World Health Organization. Global vaccine action plan. Geneva, Switzerland: World Health Organization; 2012. http://apps.who.int/iris/bitstream/10665/78141/1/9789241504980_eng.pdf?ua=1 Accessed October 01, 2019
Taiwan Centers for Disease Control. Notifiable Infectious Disease Statistics System, Taiwan. 2000-2019. https://nidss.cdc.gov.tw/ch/SingleDisease.aspx?dc=1&dt=2&disease=056 Accessed September 05, 2019
McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1-34.
Portella G, Galli C. Multicenter Italian Group for Hospital ToRC evaluation. Multicentric evaluation of two chemiluminescent immunoassays for IgG and IgM antibodies towards Rubella virus. J Clin Virol. 2010;49:105-110.
Nokes DJ, Anderson RM. Measles, mumps, and rubella vaccine: what coverage to block transmission? Lancet. 1988;2:1374.
Taiwan Centers for Disease Control. Vaccine-Preventable Diseases Control. https://www.cdc.gov.tw/En/Category/ListPage/4TFK95zgsUb9k8XYFFj2Dw. Accessed September 05, 2019.
Vilajeliu A, García-Basteiro AL, Valencia S, et al. Rubella susceptibility in pregnant women and results of a postpartum immunization strategy in Catalonia, Spain. Vaccine. 2015;33:1767-1772.
Alsibiani SA. Rubella Immunity among Pregnant Women in Jeddah, Western Region of Saudi Arabia. Obstet Gynecol Int. 2014;2014:659838.
Song N, Gao Z, Wood JG, et al. Current epidemiology of rubella and congenital rubella syndrome in Australia: progress towards elimination. Vaccine. 2012;30:4073-4078.
Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197:950-956.
Byrne L, Brant L, Reynolds C, Ramsay M. Seroprevalence of low rubella IgG antibody levels among antenatal women in England tested by NHS Blood and Transplant: 2004-2009. Is rubella susceptibility increasing? Vaccine. 2012;30:161-167.
Barlinn R, Vainio K, Samdal HH, Nordbo SA, Nokleby H, Dudman SG. Susceptibility to cytomegalovirus, parvovirus B19 and age-dependent differences in levels of rubella antibodies among pregnant women. J Med Virol. 2014;86:820-826.
Voigt EA, Haralambieva IH, Larrabee BL, et al. Polymorphisms in the wilms tumor gene are associated with interindividual variations in rubella virus-specific cellular immunity after measles-mumps-rubella II vaccination. J Infect Dis. 2018;217:560-566.
Ovsyannikova IG, Salk HM, Larrabee BR, Pankratz VS, Poland GA. Single nucleotide polymorphisms/haplotypes associated with multiple rubella specific immune response outcomes post-MMR immunization in healthy children. Immunogenet. 2015;67:547-561.
Lambert ND, Haralambieva IH, Kennedy RB, Ovsyannikova IG, Pankrantz VS, Poland GA. Polymorphisms in HLA-DPB1 are associated with differences in rubella-specific humoral immunity after vaccination. J Infect Dis. 2015;211:898-905.
Kennedy RB, Ovsyannikova IG, Haralambieva IH, Lambert ND, Pankratz VS, Poland GA. Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenet. 2014;66:493-499.
Ovsyannikova IG, Pankratz VS, Larrabee BR, Jacobson RM, Poland GA. HLA genotypes and rubella vaccine immune response: additional evidence. Vaccine. 2014;32:4206-4213.
Smits G, Mollema L, Hahné S, et al. Seroprevalence of rubella antibodies in The Netherlands after 32 years of high vaccination coverage. Vaccine. 2014;32:1890-1895.
Vandermeulen C, Mathieu R, Geert LR, Pierre VD, Karel H. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine. 2007;25:6672-6766.
LeBaron C, Forghani B, Matter L, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009;200:888-899.
Paunio M, Hedman K, Davidkin I, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect. 2000;124:263-721.
Siegrist CA. Neonatal and early life vaccinology. Vaccine. 2001;19:3331-3346.
Pichichero ME. Challenges in vaccination of neonates, infants and young children. Vaccine. 2014;32:3886-3894.
Bonhoeffer J, Siegrist CA, Heath PT. Immunization of premature infants. Arch Dis Child. 2006;91:929-935.
Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol. 2002;169:4213-4221.
Shih CT, Chang YC, Wang HL, Lin CC. Comparing the rubella seronegativity in pregnant women who received one dose of rubella vaccine at different ages in Taiwan. Vaccine. 2016;34:4787-4791.
Lin C-C, Yang C-Y, Shih Y-L, et al. Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA 27/3 in junior high school. Clin Vaccine Immunol. 2012;19:1-4.
Lin CC, Yang CY, Shih YL, et al. Rubella seroepidemiology and estimations of the catch-up immunization rate and persistence of antibody titers in pregnant women in Taiwan. BJOG. 2011;118:706-712.
Department of Statistics, Ministry of the Inferior R.O.C (Taiwan). https://www.moi.gov.tw/chi/chi_site/stat/node.aspx?cate_sn=&belong_sn=5137&sn=6868 Accessed September 05, 2019.
Tookey P. Rubella in England, Scotland and Wales. Euro Surveil. 2004;9:21-23.
Robinson JL, Canadian Paediatric Society (CPS) and Infectious Diseases and Immunization Committee. Prevention of congenital rubella syndrome. J Paediatr Child Health. 2007;12:795-797.
World health organization. https://www.who.int/immunization/newsroom/measles-data-2019/en/. Accessed September 05, 2019
Kang JH, Yoo JH. The Measles Strikes Back. J Korean Med Sci. 2019;34:e59.
Shimizu K, Kinoshita R, Yoshii K, et al. An investigation of a measles outbreak in Japan and China, Taiwan, China, March-May 2018. Western Pac Surveill Response J. 2018;9:25-31.
Zhao S. Epidemiology of an unexpected measles outbreak in Hong Kong, from March to April, 2019. Travel Med Infect Dis. 2019;30:133-136.
Chen C-J, Lee P-I, Hsieh Y-C, et al. Waning population immunity to measles in Taiwan. Vaccine. 2012;30:6721-6727.
Ho Y-H, Tsai C-C, Tsai Y-W, et al. Humoral immunity to mumps in a highly vaccinated population in Taiwan. J Microbiol Immunol Infect. 2019;52:379-385.